TB-500 10mg Research Peptide: A Complete Laboratory Guide

November 19, 2026
TB-500 10mg laboratory guide banner with the Ascend Peptides UK TB-500 10mg vial

⚠️ Research Use Only. TB-500 10mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product

TB-500 10mg is a synthetic research peptide derived from Thymosin Beta-4 (Tβ4), a naturally occurring protein involved in cellular structure, actin regulation, and intracellular organisation. Within controlled laboratory environments, this compound has become an important subject of investigation due to its interaction with cytoskeletal dynamics, cellular migration pathways, and structural signalling mechanisms.

For laboratory researchers, academic institutions and scientific professionals in the United Kingdom, TB-500 10mg provides a practical and scalable format for structured experimental work. Its targeted design allows researchers to study specific processes related to cytoskeletal dynamics in experimental models, making it a valuable tool in both foundational and advanced peptide research programmes.

This guide explores TB-500 10mg in detail, covering its molecular structure, mechanism of action, laboratory applications, and sourcing considerations while maintaining strict compliance with UK research standards.

Scientific Background: The Role of Thymosin Beta-4

To understand the relevance of TB-500, it is essential to begin with its biological foundation, Thymosin Beta-4 (Tβ4). This naturally occurring peptide is widely distributed across human tissues and is known for its role in regulating actin, a protein that forms the structural framework of cells.

Actin is responsible for maintaining cell shape, enabling movement, and supporting intracellular transport. It exists in two forms:

  • G-actin (globular form)

  • F-actin (filamentous form)

The transition between these forms is a dynamic process that determines how cells behave under different conditions. Thymosin Beta-4 regulates this process by binding to actin monomers and controlling their availability for polymerisation.

TB-500 is a synthetic peptide corresponding to a short segment of the actin-binding region of Thymosin Beta-4 (Tβ4), the parent protein. Most published work on actin binding, cell migration and tissue models used full-length Tβ4, and those findings do not automatically apply to the fragment. One in-vitro study found that the seven-amino-acid actin-binding motif showed activity close to full-length Tβ4 in endothelial cell migration and aortic-ring sprouting assays (Philp et al., 2003).

Structural Identity and Functional Properties

TB-500 is a short-chain peptide corresponding to part of the actin-binding region of Thymosin Beta-4.

It is typically supplied as a lyophilised (freeze-dried) powder, which helps maintain stability during storage and transport.

Core structural advantages:

  • Focused amino acid sequence targeting actin interaction

  • Stability in lyophilised form

  • Compatibility with multiple experimental models

  • Scalable 10mg format for extended research use

These properties make TB-500 particularly suitable for reproducible and controlled research environments.

TB-500 in the Broader Peptide Landscape

In peptide research, each compound is typically associated with a specific biological pathway. TB-500 is studied mainly in relation to actin, an intracellular structural protein, rather than receptor-mediated signalling.

For example, peptides discussed in the GH-axis research peptides are primarily involved in growth hormone signalling pathways. These compounds interact with receptors and influence endocrine responses in laboratory models.

Similarly, compounds covered in the IGF-1 LR3 research guide operate within growth factor pathways, focusing on receptor activation and downstream signalling cascades.

TB-500 research focuses on intracellular structural proteins such as actin rather than receptor signalling. It is sometimes studied alongside other peptides to explore how structural and signalling systems interact.

Key distinctions:

  • TB-500 → Cytoskeletal and structural focus

  • GHRH analogues → Hormone signalling pathways

  • Growth factors → Receptor-driven pathways

This positioning makes TB-500 a complementary tool in multi-pathway research programmes.

TB-500 actin interaction cytoskeleton research diagram

Research Use Only: TB-500 is a research-use compound. Research is ongoing, and no medical, therapeutic, or performance claims are intended. This is a schematic illustration only and not proof of mechanism, safety, or clinical use. 

Mechanism of Action: A Closer Look

The steps below are characterised mainly for full-length Thymosin Beta-4; how far the TB-500 fragment reproduces each step has been studied much less.

Step-by-step mechanism:

1

Actin BindingThymosin Beta-4 binds G-actin monomers, influencing their availability for polymerisation; TB-500 contains the central actin-binding motif of that protein.
2

Regulation of PolymerisationBy controlling the transition from G-actin to F-actin, the peptide affects how structural filaments are formed.
3

Cytoskeletal ReorganisationChanges in actin dynamics alter cytoskeletal organisation and cell migration in laboratory models.
4

Cellular Movement DynamicsBecause actin is essential for movement, these structural changes influence how cells migrate and reposition.
5

Interaction with Signalling PathwaysIn vitro, the actin-binding motif has been reported to promote endothelial cell migration and vessel sprouting (Philp et al., 2003).

Research Applications of TB-500 10mg

TB-500 10mg has been explored across multiple areas of laboratory research due to its targeted mechanism and versatility.

Primary research applications:

Cytoskeletal studies
Researchers use TB-500 to examine how actin filaments form and reorganise under different conditions.

Cellular migration models
It has been studied in endothelial cell migration experiments.

Angiogenic pathway research
TB-500 is included in studies focused on endothelial cell behaviour and vascular signalling mechanisms.

Multi-peptide interaction studies
In advanced research programmes, TB-500 is combined with other peptides to explore pathway interactions.

These applications demonstrate the compound’s relevance across a broad range of research disciplines.

Why the 10mg Format Matters

The 10mg format of TB-500 is widely used because it provides both flexibility and consistency in laboratory settings. Researchers conducting multi-phase experiments require sufficient material to maintain uniform conditions across trials.

Benefits of the 10mg format:

  • Supports extended research protocols

  • Enables comparative and multi-variable studies

  • Aligns with commonly used research quantities

  • Improves efficiency in long-term projects

Whatever the format, researchers should review the testing record for the batch they receive.

Sourcing TB-500 10mg in the United Kingdom

Sourcing high-quality research peptides is essential for ensuring reliable and reproducible results. In the UK, researchers prioritise suppliers that meet strict quality standards and provide full transparency.

When reviewing the TB-500 10mg research peptide, researchers can assess specifications, batch information, and availability within a research-focused framework. This level of transparency is critical for maintaining experimental integrity.

Many laboratories also explore additional compounds when designing research protocols. The collection provides access to a wide range of peptides used in multi-pathway studies. For a broader understanding of available products and sourcing standards, visiting Ascend Peptides UK offers a complete overview of the platform and its research-driven approach.

Ascend Peptides UK publishes independent Janoshik reports for tested batches; each report applies to the batch it names and covers only the analyses it lists.

Key quality indicators:

  • Published Janoshik reports (see CoA page)

  • Reports state the analyses run

  • Batch-specific Certificate of Analysis

  • Lyophilised format

  • Clear research-use-only labelling

TB-500 10mg research peptide product UK supplier

Regulatory Compliance and Responsible Research

In the United Kingdom, TB-500 10mg has no marketing authorisation as a medicine. It is not approved for human consumption and must only be used within laboratory environments.

Both institutional buyers and individual researchers are responsible for ensuring compliance with UK regulations. Suppliers such as Ascend Peptides UK clearly label their products for research use only, supporting responsible sourcing and usage.

Conclusion

TB-500 10mg remains a valuable tool in peptide laboratory research to investigate actin‑related cytoskeletal dynamics. Its compatibility with multi-pathway studies makes it particularly useful for researchers exploring complex biological systems.

For UK-based laboratories and research-focused buyers, the TB-500 10mg product page lists the published testing record for tested batches. Related compounds, including BPC-157 and GHK-Cu, are grouped on the recovery research peptides page.

Frequently Asked Questions (FAQs)

What is TB-500 10mg used for in research?
TB-500 10mg is used in laboratory studies focused on actin regulation and cytoskeletal organisation. It is commonly included in experiments analysing cellular movement and structural behaviour. All use is limited strictly to controlled research environments.
What is TB-500 derived from?
TB-500 is derived from Thymosin Beta-4, a naturally occurring peptide found in many cell types. TB-500 corresponds to a short segment of its actin-binding region; findings for full-length Thymosin Beta-4 do not automatically apply to the fragment.
How is TB-500 different from other peptides?
TB-500 carries the actin-binding motif of thymosin β4, so it is studied in relation to actin rather than receptor or hormone signalling; direct actin binding by the isolated fragment is less well documented than for the full protein. It is often used alongside other compounds in multi-pathway research.
Why is the 10mg format commonly used?
The 10mg format provides sufficient material for structured and multi-run experiments. It helps maintain consistency across research protocols. This makes it suitable for both small-scale and advanced studies.
Is TB-500 legal in the UK?
TB-500 has no UK marketing authorisation as a medicine, and Ascend Peptides UK supplies it for in-vitro laboratory research only. It is on the WADA Prohibited List (section S2). Whether a particular purchase or use is lawful depends on the circumstances, so buyers are responsible for checking the law and their institution’s rules.
What purity level is required?
A certificate should state purity, measured content and the analytical method, and ideally an identity result such as mass spectrometry. Ascend’s published Janoshik report for TB-500 10mg states measured content and purity for the tested vial; it does not state the analytical method or which peptide sequence was quantified.
Can TB-500 be used in multi-peptide studies?
It can be, although published studies combining TB-500 with other peptides are few and do not establish additive effects.
Where can TB-500 10mg be sourced in the UK?
TB-500 10mg can be sourced from suppliers such as Ascend Peptides UK. Published Janoshik reports for tested batches are listed on the product page and the CoA page.
What format is TB-500 supplied in?
TB-500 is supplied as a lyophilised powder. This format helps protect stability during storage and transport.

References

  • Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103–2105. PubMed 14500546
  • Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin β4 mapped by mutational analysis. EMBO J. 1996;15(2):201–210. PubMed 8617195
  • Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. J Chromatogr A. 2012;1265:57–69. PubMed 23084823

DISCLAIMER

All products supplied by Ascend Peptides UK are intended strictly for research purposes only. They are not intended for human consumption or for any therapeutic, diagnostic, or clinical use. None of the items offered are classified as medicinal products by the MHRA. It is the buyer’s responsibility to ensure all purchases comply with applicable laws and regulations. Ascend Peptides UK accepts no liability for misuse.